Pulmatrix Operating Income 2014-2022 | PULM
Pulmatrix operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Pulmatrix Annual Operating Income
(Millions of US $) |
| 2021 |
$-20 |
| 2020 |
$-10 |
| 2019 |
$-21 |
| 2018 |
$-20 |
| 2017 |
$-17 |
| 2016 |
$-25 |
| 2015 |
$-23 |
| 2014 |
$-9 |
| 2014 |
$-3 |
| 2013 |
$-0 |
| 2013 |
$-1 |
| 2012 |
$-1 |
Pulmatrix Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-8 |
| 2021-06-30 |
$-4 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-3 |
| 2020-09-30 |
$-1 |
| 2020-06-30 |
$-1 |
| 2020-03-31 |
$-5 |
| 2019-12-31 |
$-4 |
| 2019-09-30 |
$-4 |
| 2019-06-30 |
$-8 |
| 2019-03-31 |
$-5 |
| 2018-12-31 |
$-4 |
| 2018-09-30 |
$-5 |
| 2018-06-30 |
$-6 |
| 2018-03-31 |
$-5 |
| 2017-12-31 |
$-4 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-5 |
| 2017-03-31 |
$-3 |
| 2016-12-31 |
$-7 |
| 2016-09-30 |
$-3 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-5 |
| 2015-12-31 |
$-4 |
| 2015-09-30 |
$-5 |
| 2015-06-30 |
$-11 |
| 2015-03-31 |
$-3 |
| 2014-12-31 |
$-2 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$-2 |
| 2014-03-31 |
$-1 |
| 2013-12-31 |
$-1 |
| 2013-09-30 |
$-1 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.017B |
$0.005B |
|
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|
